Abstract
Lactobacillus reuteri CRL1101 was found to reduce inflammatory and oxidative damage during endotoxic shock induced by lipopolysaccharide (LPS) administration in mice. This beneficial effect was related to the capacity of both the cell structure as well as their secreted products to act synergistically to induce a tolerogenic profile in immune cells. The study supports the idea that, although probiotic microorganisms may exert their beneficial effects due to their well-known ability to modulate intestinal immunity, these effects are not restricted to the gastrointestinal tract. In addition, we demonstrated that the in vitro screening of lactobacilli strains is still a powerful approach to discriminate the potential probiotic bacteria for specific functions that could be later studied in animal models. From the systematic studies reported here, L. reuteri CRL1101, a strain with technological potential usefulness in dairy products, is proposed as novel probiotic candidate for the prevention and control of systemic inflammatory disorders.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
